

Exhaled Nitric Oxide, Bronchial Hyperresponsiveness and Spirometric Parameters in Patients with Allergic Rhinitis during Pollen Season

Michael P. Makris¹, Christina Gratziou², Xenophon S. Aggelides¹, Sokratis P. Koulouris¹,
Ioanna Koti¹, and Dimitrios C. Kalogeromitros¹

¹ Allergy Clinical Research Center, Allergy Unit, "Attikon" University Hospital, Medical School,
University of Athens, Athens, Greece

² Asthma and Allergy Center, Evgenidion Hospital, Medical School, University of Athens, Athens, Greece

Received: 24 March 2011 ; Received in revised form: 19 June 2011 ; Accepted: 25 June 2011

ABSTRACT

Allergic rhinitis and asthma share common epidemiological features and inflammatory processes. The aim of the present study was to document the influence of natural allergen exposure in exhaled NO (eNO) and in spirometric parameters of patients with seasonal allergic rhinitis (SAR) and to investigate the differences among subjects with positive versus negative bronchial provocation to metacholine (BP_{Mch}).

Twenty-six non-smoking patients (13F/13M; mean age 28.4ys) with a documented history of SAR, 15 healthy, non-atopic (6F/9M; mean age 37.1ys) and 6 non-symptomatic atopic subjects (3F/3M; mean age 36.5ys) were studied. At the first visit during pollen season each subject filled symptom-score card, underwent eNO and nasal NO (nNO) measurements and spirometry. BP_{Mch} was performed within the next 10 days. At the second visit out of pollen season, all measurements but BP_{Mch} were repeated. Control subjects underwent eNO and nNO measurements.

eNO was significantly increased during pollen season in BP_{Mch} positive vs BP_{Mch} negative (46.22±32.60 vs 17.81±12.67, $p=0.014$) and vs non-atopic controls (11.40±5.84, $p<0.001$) as well as atopic controls (13.56±5.34, $p=0.001$). No difference was detected out of pollen season in both patients' groups. nNO values were increased only in BP_{Mch}(+) group compared to both control groups in pollen season (vs non-atopics $p=0.002$, vs atopics $p=0.002$) and only vs non-atopics out of season, $p=0.004$. Regression analysis has shown that the difference in FEF₂₅₋₇₅ values (off season-in season) is a predictor of positive BP_{Mch}.

eNO is markedly increased in BP_{Mch} patients with allergic rhinitis while mid-expiratory flow may represent an early marker of lower airway involvement in respiratory allergy.

Keywords: Allergic rhinitis; Asthma; Bronchial hyperresponsiveness; Exhaled nitric oxide; Spirometry

Corresponding Author: Michael P. Makris, MD, PhD
Consultant in Allergy, Allergy Unit, Attikon University Hospital, 1,
Rimini str, Xaidari, PC 12462 Athens, Greece.

Tel: (+30 21) 0583 2450, Fax: (+30 21) 0583 2454
E-mail: mmakris.allergy@gmail.com

INTRODUCTION

Allergic rhinitis is a common IgE-mediated inflammatory condition of the upper airways which is often associated with several co-morbidities that include allergic conjunctivitis, sinusitis, otitis media and asthma.¹ Epidemiological studies consistently report that 60 to 85% of patients with asthma have concomitant allergic rhinitis, whereas up to 40% of patients with allergic rhinitis have clinically demonstrable asthma.² Furthermore, several studies have shown that asthma and rhinitis share common inflammatory processes although the exact pathophysiological interactions between upper and lower airways still remain unclear.³

Asthma is characterized by a reversible airflow obstruction and forced expiratory volume in the first second (FEV₁) is considered the gold standard to evaluate bronchial obstruction.⁴ Recent evidence support the importance of small airways' involvement in the pathogenesis of asthma.⁵ So, the forced expiratory flow at the 25% and 75% of the pulmonary volume (FEF₂₅₋₇₅) as an indirect marker of small airways assessment might be more sensitive to obstruction in small airways than FEV₁. Besides, it has been demonstrated that both FEV₁ and mainly FEF₂₅₋₇₅ are impaired in patients with allergic rhinitis without symptoms from the lower airways.⁶ The FEF₂₅₋₇₅ has been proposed as a reliable marker of early bronchial impairment in allergic rhinitis.⁷

Bronchial hyperresponsiveness (BHR) a distinct feature of pathophysiology in asthma, has been shown to reach a great prevalence among patients with allergic rhinitis; affecting almost 50% of seasonal AR sufferers and 70% of those with perennial symptoms.⁸ The occurrence of non-specific BHR in a proportion of non-asthmatic individuals with AR seems to reflect subclinical inflammatory processes in the lower airways. In such patients increased eosinophilic counts and high levels of eosinophilic cationic protein (ECP) have been demonstrated at the peak of their pollen season.⁹ AR has shown to be a predisposing factor for later developing asthma and the transition from rhinitis only to the development of clinical asthma is probably a gradual one, with BHR representing an intermediate step.¹⁰

Nitric oxide, a free radical gas that diffuses freely from its site of production has multiple biological and pathophysiologic functions. As exhaled nitric oxide

(eNO) is increased in asthmatic patients and its levels is well correlated with the presence and level of inflammation while it decreases with glucocorticoid treatment¹¹. Because the biomarker is non invasively and easily collected, it has the potential to be used not only as a diagnostic tool but also as a management tool for assessing severity, monitoring response to therapy, and gaining control of asthma symptoms. Moreover, numerous studies have shown increased levels of eNO in patients with AR without asthma^{12,13} suggesting that this finding could represent an early marker of an underlying ongoing inflammation in the lower respiratory tract.

Seasonal AR (SAR) represents the prevalent type of the disease in Mediterranean countries and although the new clinical terminology according to ARIA guidelines¹⁴ may be more useful in clinical practice, the intermittent allergen exposure during pollen season combined with the minimal persistent inflammation¹⁵ that remains set important research issues.

The aim of the present study was to document the influence of natural allergen exposure on eNO as well as on spirometric parameters of patients with SAR and furthermore to investigate the possible differences among subjects with positive vs negative BHR as reflected by bronchial provocation to metacholine (BP_{Mch}). The possible relationship of the above mentioned parameters in patients with SAR without asthma was the secondary goal of this study.

PATIENTS AND METHODS

Patients Characteristics

Twenty-six non-smoking patients (13 females and 13 males; mean age 28.4 years, age range 16-47 years) with a documented history of SAR at least the last two consecutive years were recruited from the Allergy Unit of "Attikon" University Hospital. The diagnosis of SAR was based on the typical clinical symptoms and the documentation of sensitization with skin prick tests (SPTs), to at least one major inhalant allergen in Greece (*Grasses sp*, *Parietaria spp* or *Olea europea*). Asthma was definitely absent in study participants based on symptoms as well as of the absence of abnormal variability in pulmonary function by spirometry, reversibility and PEF monitoring.

Exclusion criteria for patients recruitment were: a- sensitization in perennial allergens also, b- seasonal symptoms non consistent with the pollen season of the

Parameters of Allergic Rhinitis During Pollen Season

offending allergens, c- asthma or past history of antiasthmatic medication during the last two years, d- symptoms or signs of upper or lower airway infection during the last 30 days before inclusion to the study as well as use of nasal or oral corticosteroids or antihistamines during this time period and e- pregnancy.

As control groups, 15 healthy, non-atopic (6 females and 9 males; mean age 37.1 years, age range 27-56 years) and 6 non-symptomatic atopic subjects (3 females and 3 males; mean age 36.5 years, age range 31-43 years) were studied. All control subjects were non-smokers without respiratory tract infection within 30 days prior to the investigation. The Ethics Committee of "Attikon" University Hospital approved the study and written informed consent was obtained from each patient and control subject. Patient anonymity was preserved.

Study Design

Upon entry of patients into the study (December 2007- January 2008, out of pollen season) a detailed history was taken and physical examination and SPTs in inhalant allergens were performed. In all study participants total serum IgE concentration in IU/ml, (UniCAP system, Phadia, Uppsala, Sweden) and measurement of eosinophils in peripheral blood (cells per count) were carried out.

Subjects attended the Allergy Clinic on two occasions, 5-7 months apart. At the first visit (March-May 2008, in pollen season) each subject filled symptom score card, underwent eNO and nasal NO (nNO) measurements and spirometry. BPMch was performed within the next 10 days. At the second visit (November-December 2007, out of pollen season) except BPMch the same investigation was carried out.

Control subjects underwent eNO and nNO measurements at the time period of the first visit.

Symptom Scores

The patients gave an overall assessment of their rhinitis symptoms in both visits. Symptoms of rhinorrhea, nasal blockage, sneezing, nasal itching, sense of postnasal drip/pharynx irritation and eye streaming/itching were rated on a four-point scale (0= no symptoms, 1= mild, 2= moderate and 3= severe). The sum of the above mentioned symptom scores ranging from 0 to 18, was included in study analysis.

Skin Prick Tests

Atopy was assessed in all subjects (patients and controls) by skin prick tests, using a battery of 22 common inhalant allergens: Dermatophagoides Pteronyssinus, Dermatophagoides Farinae, Phleum pr, Cynodon D, Lolium per, Secale cer, Parietaria off, Artemisia vul, Taraxacum Vulg, Plantago lan, Olea Europea, Platanus, Betula, Quercus, Fagus, Poplar, Cat dander, Dog epithelium, Cladosporium, Penicillium, Alternaria Alt, Aspergillus mix; positive (histamine hydrochloride 10 mg/dl) and negative control (normal saline) were also used (Stallergenes, Paris, France). A wheal diameter >3 mm was considered as criterion of positive skin prick test. For methodological reasons patients were classified as monosensitized (sensitization in Parietaria, Olea or grasses) and polysensitized (more than one of the above allergens). Positive SPTs in more than one species of grasses was considered as monosensitization due to the well-documented extended cross-reactivity.

Spirometry and Bronchial Provocation Tests

A MasterScope spirometer (Erich Jaeger, Wurzburg, Germany) was used for flow volume spirometry. The best of three maneuvers was expressed as a percentage of the predicted value.

Bronchial hyperreactivity was assessed by a methacholine provocation test (BP_{Mch}) that took place in Asthma and Allergy Center of the Pulmonary and Critical Care Clinic of University of Athens at Evgenidion Hospital. The methacholine solution (Lopharma, Milan, Italy) was nebulized with a hand-held nebulizer (Dosimeter MB3, MEFAR Bovezzo, Italy). The challenge test was continued with increasing doubling doses up to the dose of methacholine that caused a 20% drop of the baseline FEV_1 value or up to the point where the maximum dose (800 mg) was inhaled. The PD_{log20} was calculated automatically by extrapolation of the logarithmic dose response-curve as the cumulative dose causing a 20% fall in FEV_1 . In case of FEV_1 decline >10% after the initial dose of 0.9% NaCl the BP_{Mch} test was considered positive and PD_{log20} value was arbitrarily set at <0.01 mg. Patients with positive test even at the maximum dose were considered as BP_{Mch} positive.

NO Measurements

Exhaled and nNO were measured with a fast response chemiluminescence analyzer (Analyser CDL

88 sp, ECO MEDICS, Duernten, Sweden) by the online single breath technique, according to the ATS and ERS recommendations¹⁶. The analyzer had a sampling rate of 200 ml/min and a detection rate of 0.1 to 5000 parts per billion (ppb).

Briefly, during eNO measurement procedure, the subjects were asked to perform a single slow exhalation starting from total lung capacity through a mouthpiece and a one-way non-rebreathing valve against a resistance of 16 cm H₂O under a visual biofeedback, to maintain a 50 ml/sec steady flow. Subjects were at rest, sitting down, having refrained from eating and exercise for at least 1 hour, and breathed filtered NO-free air (Denox 88, ECO MEDICS, Duernten, Sweden) without a nose-clip before the single exhalation maneuver.

Ambient air NO was recorded before and after each test. The analyzer was calibrated daily with a zero signal and certified NO/N₂ calibration gases. eNO concentration was measured at the plateau (≥ 2 sec during an exhalation ≥ 6 sec) of the end-exhaled reading and expressed as ppb.

The nNO was measured via the same equipment with the best validated method of aspiration at constant flow rate (3 L/minute) from one naris with gas entrained via the other naris. Slow oral exhalation against a resistance of 16 cm H₂O closed the velum reliably thus, preventing leak of nasal NO via the posterior velopharyngeal aperture.

Statistical Analysis

Data of quantitative (continuous) variables are presented as mean and standard deviation (SD). Normality of distribution was examined with Kolmogorov-Smirnov and Shapiro-Wilk's test. In cases that normal distribution was assessed paired or independent t-test was used for differences of means. In case of a non-normal distributed characteristic, a Mann-Whitney test was carried out.

Chi-square test was used to compare differences in categorical variables (sex, type of sensitization etc). Crude and adjusted correlations of total serum IgE were investigated with Pearson and Spearman's rho test coefficient. The existence of possible relations between parameters was assessed with chi-square test, linear and logistic regression.

A two tailed *p*-value less than 0.05 was considered to indicate statistical significance. All analyses were performed with the Statistical Package for Social Science (SPSS, Chicago, IL, USA), version 13.0.

RESULTS

In the whole Study Population

The duration of SAR symptoms in study population had a mean value 9.8 years (range=2-25, SD=5.85). The mean IgE was 489.38 IU/ml (range=17.7-4416.0, SD=912.08) and the eosinophils in peripheral blood 331.28 per mm³ (range=65-760, SD=209.86). The 11 out of 26 (42.3%) patients were monosensitized and 18/26 (69.23%) had positive BP_{Mch}.

The eNO, nNO measurements and the spirometric values of all study subjects are presented in table 1a, while the NO values of non atopic controls are shown in table 1b and of atopic in table 1c respectively. Both eNO and nNO have shown statistically significant increased values during pollen season while no differences were detected in spirometric parameters.

eNO of patients in comparison with non-atopic controls was significantly higher during pollen season ($P=0.001$); in contrary no difference was detected at the 2nd measurement out of pollen season ($P=0.517$). Referring to atopic controls, the SAR group showed increased eNO values during pollen season that almost reached statistical significance ($P=0.051$) while out of pollen season no difference was shown ($P=0.981$).

nNO measurements in and out of pollen season showed no difference with both control groups (in season versus (vs) non-atopics $P=0.086$, out of season vs non-atopics $P=0.248$, in season vs atopics $p=0.106$, out of season vs atopics $P=0.32$).

According to Bronchial Hyperresponsiveness

Nine out of 18 BP_{Mch} positive patients [BP_{Mch} (+)] were males (50%) while the proportion in BP_{Mch} negative patients [BP_{Mch} (-)] was 5/8 (62.5%), $P=0.43$. Referring to pattern of sensitization 7/18 (38.9%) of BP_{Mch} (+) and 3/8 (37.5%) of BP_{Mch} (-) were monosensitized ($P=0.64$).

According to BP_{Mch} result 18 patients were positive (mean age 27.72 ± 8.90 ys, symptom onset 10.67 ± 6.25 ys) while 8 patients were negative (mean age 28.88 ± 8.18 ys, symptom onset 7.63 ± 4.72 ys). The total IgE showed a value of 324.57 ± 332.78 IU/ml in BP_{Mch} positive and 1041.30 ± 1897.96 IU/ml in BP_{Mch} negative patients. The number of eosinophils/mm³ in peripheral blood was 357.27 ± 212.30 and 201.33 ± 168.70 , respectively. The PDlog20 in Mch positive patients showed a mean value of 249.03 ± 295.29 mg.

Parameters of Allergic Rhinitis During Pollen Season

Table 1. eNO and nNO values and spirometric parameters in study population; 1a: patients, 1b: non-atopic controls, 1c: atopic controls.

Table 1a.

Mean $\pm$ SD	Measurement		Statistic	p-value
	In season n=26	Out of season n=26		
eNO	35.86 $\pm$ 30.70	16.05 $\pm$ 11.97	z = 3.62	<0.001
nNO	1387.46 $\pm$ 965.29	1015.06 $\pm$ 643.39	t = 2.69	0.012
FEV1 (%predicted)	97.64 $\pm$ 9.65	96.18 $\pm$ 11.22	t = 0.94	0.355
FEF ₂₅₋₇₅ (%predicted)	89.19 $\pm$ 18.94	87.80 $\pm$ 17.64	t = 0.505	0.618
FEV1/FVC	84.42 $\pm$ 5.114	84.19 $\pm$ 4.26	t = 0.28	0.781
Nasal symptom score	7.54 $\pm$ 3.72	0.92 $\pm$ 2.61	z = 4.14	<0.001

Table 1b.

9 males / 6 females	Minimum (Min)	Maximum (Max)	Mean	SD
eNO in pollen season	3.90	24.50	11.40	5.83671
nNO in pollen season	499.40	1110.60	774.95	179.55847

Table 1c.

3 males / 3 females	Minimum (Min)	Maximum (Max)	Mean	SD
eNO in pollen season	8.70	18.30	13.56	5.33661
nNO in pollen season	381.20	1110.00	742.83	279.95044

The eNO and nNO measurements and the spirometric values of BP_{Mch} (+) and BP_{Mch} (-) are presented in table 2. The values of eNO during and off pollen season in patients' groups in comparison with controls are presented in figure 1; BP_{Mch} (+) showed

significantly higher values in pollen season vs both control groups and this difference remained significant only vs non-atopics out of pollen season. In contrary, no differences were detected in BP_{Mch} (-) group.

Table 2. eNO and nNO values and spirometric parameters according to bronchial hyperresponsiveness

Mean $\pm$ SD	BPMch		Statistic	p-value
	Negative	Positive		
eNO in pollen season	17.81 $\pm$ 12.67	46.22 $\pm$ 32.60	z = 2.45	0.014
eNO off season	8.45 $\pm$ 8.02	19.73 $\pm$ 11.59	z = 2.59	0.010
nNO in pollen season	807.27 $\pm$ 471.57	1703.55 $\pm$ 1025.02	z = 2.39	0.017
nNO off season	811.36 $\pm$ 594.28	1155.74 $\pm$ 631.89	t = 1.30	0.20
Symptom score in season	7.12 $\pm$ 4.55	7.94 $\pm$ 3.40	t = 1.28	0.13
Symptom score off season	0.25 $\pm$ 0.71	1.17 $\pm$ 3.09	z = 0.57	0.72
FEV1(% predicted) in pollen season	100.62 $\pm$ 7.07	96.68 $\pm$ 10.70	t = 0.95	0.35
FEV1(% predicted) off pollen season	97.62 $\pm$ 6.39	96.49 $\pm$ 12.49	z = 0.89	0.37
FEF ₂₅₋₇₅ (% pred) in pollen season	100.62 $\pm$ 22.78	85.35 $\pm$ 14.47	t = 2.04	0.053
FEF ₂₅₋₇₅ (% pred) off pollen season	91.37 $\pm$ 17.44	87.11 $\pm$ 16.99	t = 0.58	0.56
FEV1/FVC in pollen season	86.87 $\pm$ 5.46	83.41 $\pm$ 4.83	z = 1.61	0.107
FEV1/FVC off pollen season	84.87 $\pm$ 3.18	84.16 $\pm$ 4.48	t = 0.41	0.68
FEF ₂₅₋₇₅ (% pred) difference off -in pollen season	-9.25 $\pm$ 15.72	2.41 $\pm$ 12.24	t = 2.03	0.054




Figure 1. eNO in and off season in BP_{Mch}(+) and BP_{Mch}(-) patients' groups compared with controls.

nNO values were increased only in BP_{Mch}(+) group compared to both control groups in pollen season (vs non-atopics $P=0.002$, vs atopics $P=0.002$) and only vs non-atopics out of season, $P=0.004$.

Correlation Analysis

Total serum IgE values did not correlate with eNO and nNO values in both time points. Similarly, no correlation was detected between symptom scores with eNO, nNO and spirometric values.

The BP_{Mch}(+) did not correlate with the pattern of sensitization (polysensitized or monosensitized); in contrary regression analysis has shown that the difference in FEF₂₅₋₇₅ values (off season- in season) represents significant predictor of positive BP_{Mch} result. Finally, in BP_{Mch}(+) group PDlog20 did not correlate, although a trend was observed, with eNO values as shown in figure 2.

DISCUSSION

The results of the present study assessed in subjects with SAR, as sole clinical manifestation of respiratory allergy, that the natural exposure to the allergens during pollen season induces elevated eNO levels that return almost to normal values after the cessation of exposure. These findings were confirmed in comparison with both non-atopic and atopic control subjects. Furthermore, our data clearly demonstrate that elevated eNO concentration is strongly associated with the presence of bronchial hyperresponsiveness in this population; BP_{Mch}(+) represents an important factor that determines the increased NO levels detected in exhaled air of subjects with SAR. Moreover, an important finding of this study was that FEF₂₅₋₇₅ parameter is lower during pollen season in SAR patients with bronchial hyperresponsiveness, suggesting that its decrease compared with out of pollen season values could represent an early sensitive

Parameters of Allergic Rhinitis During Pollen Season




Figure 2. Correlation of eNO in season with PDlog20 in BP_{Mch}(+) patients.

marker of lower airways' inflammation in patients with nasal symptoms only.

Referring to eNO, the results of the present study are in agreement with those of our previous works^{17,18} that have shown increased eNO levels in SAR patients during pollen season and with data from other researchers in pediatric^{19,20} and adult population.²¹ In the present study, no difference was detected in eNO levels between non atopic and atopic controls consistently to another previous study of our group.¹⁷ In contrary, other studies report increased eNO in healthy, non smokers atopics compared to non-atopics with similar characteristics²² while Prasad et al have shown that healthy atopic children showed higher eNO levels than healthy non-atopic as well as the non-atopic children with asthma.²³ Olin et al provides an interesting explanation for these rather confusing results showing that only atopic subjects that are exposed to the offending allergen show increased eNO levels while their values are within the normal range out of pollen season²⁴. However, in our study this does not seem to be the case, as we have performed the eNO measurements in the controls during pollen season. Another remarkable finding is that in the whole study population the increased eNO levels turned to normal

values out of pollen season; in contrary Prieto et al. report that eNO concentrations decreased from 63.1 ppb during the pollen season to 30.2 ppb out of season but were still significantly increased when compared with healthy controls (12.8 ppb),²⁵. Our findings suggest that atopic status is not the most important determinant of enhanced NO production as others believe; however, the small sample size does not allow us to reach definite conclusions.

A primary aim of the study was to determine differences in eNO concentrations between subjects with SAR with increased responsiveness to metacholine and subjects with normal responsiveness. The results of our study demonstrate that the presence of increased responsiveness to direct stimulus is associated with increased concentrations of eNO. Studies dealing with eNO correlation with bronchial responsiveness refer in vast majority in subjects with allergic asthma; the conclusions vary as some researchers report positive correlation^{26,27} while others failed to find such relation in children with mild intermittent asthma²⁸ and in adults with mild-moderate asthma.²⁹ A small study in fourteen subjects with SAR reported increased concentration of eNO in subjects with seasonal rhinitis and increased responsiveness to metacholine and adenosine-5-monophosphate,²⁵ while

the same group in a population of thirty-eight adults with SAR, found increased eNO levels during pollen season in subjects with as well as without bronchial hyperresponsiveness.³⁰ Although a correlation trend was observed between eNO and $Pdlog20$ in $BP_{Mch}(+)$ this finding did not reach statistical significance; the same was reported in a previous study in allergic rhinitis³⁰ while a well-designed study in fifty-three asthmatics adults reported significant correlation of these two parameters.³¹ A possible interpretation could be that the correlation of eNO with $Pdlog20$ cannot be observed in the phenotype of mild respiratory allergy – allergic rhinitis only and/or mild asthma- and is more prominent in more severe forms of asthma.

An important finding in the present study is the demonstration of lower mid-expiratory values in spirometry of SAR patients with bronchial hyperresponsiveness during pollen season. Our data are in full accordance with those reported by Ciprandi et al. that found lower FEF_{25-75} values in 65/121 (53.7%) of patients with persistent allergic rhinitis.³² According to some authors, FEF_{25-75} that reflects predominantly small airway caliber might represent an early indicator of reduced lung function in patients with allergic rhinitis.³³

Referring to eNO correlation with total serum IgE and the pattern of sensitization, we failed to prove such a relation. In contrary Mete et al. report that the number of positive SPTs in subjects with allergic rhinitis correlates with the severity of bronchial hyperresponsiveness.³⁴ In accordance other researchers have found that in pediatric population with allergic rhinitis or asthma, eNO concentration correlates with the number of positive SPTs and total serum IgE concentration.²⁶ The small sample size of our study and the categorization of our population in poly and monosensitized are possible reasons for our contradictory results.

Nasal NO concentration was increased during pollen season only in patients with bronchial hyperresponsiveness, while in the whole population no difference was detected in comparison with both control groups. Data from previous studies are also inconclusive: Kharitonov et al. reported increased nNO concentration in untreated AR patients³⁵ while Moody *et al.* found no difference compared with controls in subjects with perennial allergic rhinitis.³⁶

In conclusion, the results of this study confirm the elevated eNO levels during pollen season in SAR

patients, but furthermore show a clear correlation between bronchial hyperresponsiveness and eNO and suggest that mid-expiratory flow may represent an early marker of lower airway involvement in respiratory allergy. Our findings strongly support the use of these parameters in clinical practice for the close monitoring of patients with allergic rhinitis. Our study, in concordance with other recent studies,³⁷ imply that lower airway inflammation may exist in patients with allergic rhinitis even in the absence of lower airways' symptoms.

ACKNOWLEDGEMENTS

All authors would like to express their gratitude to Mrs. Aikaterini Kyriakopoulou for her donation of the equipment for NO measurements (Analyser CDL 88 sp, ECO MEDICS, Duernten, Sweden) to the Allergy Unit of Attikon University Hospital, University of Athens.

All co-authors have no conflict of interest to declare.

REFERENCES

1. Ait-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J. The ISAAC Phase Three Study Group. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. *Allergy* 2009; 64 (1):123-48.
2. Linneberg A, Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. *Allergy* 2002; 57(11):1048-1052.
3. Togias A. Systemic cross-talk between the lung and the nose. *Am J Respir Crit Care Med* 2001; 164(5):726-7.
4. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J* 2005; 26 (5):948-68.
5. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, et al. Inflammation of small airways in asthma. *J Allergy Clin Immunol* 1997; 100(1):44-51.
6. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? A population based study. *Allergy* 2005; 60(7):882-7.
7. Ciprandi G, Cirillo I, Klersy C, Marsegli GL, Vizzaccaro A, Pallestrini E, et al. Role of FEF_{25-75} as an

Parameters of Allergic Rhinitis During Pollen Season

- early marker of bronchial impairment in patients with seasonal allergic rhinitis. *Am J Rhinol* 2006; 20(6):641-7.
8. Ciprandi G, Cirillo I, Tosca MA, Vizzaccaro A. Bronchial hyperreactivity and spirometric impairment in patients with perennial allergic rhinitis. *Int Arch Allergy Immunol* 2004; 133(1):14-8.
 9. Polosa R, Ciamarra I, Mangano G, Prosperini G, Pistorio MP, Vancheri C, et al. Bronchial hyperresponsiveness and airway inflammation markers in non asthmatics with allergic rhinitis. *Eur Respir J* 2000; 15(1):30-35.
 10. Porsbjerg C, von Linstow ML, Ulric CS, Nepper-Christensen SC, Backer V. Outcome in adulthood of asymptomatic airway hyperresponsiveness to histamine and exercise-induced bronchospasm in childhood. *Ann Allergy Asthma Immunol* 2005; 95(2):137-42.
 11. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. *Am J Respir Crit Care Med* 1996; 153(1):454-7.
 12. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D. Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. *Clin Exp Allergy* 2003; 33(11):1506-11.
 13. Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, et al. Association between nasal and bronchial symptoms in subjects with persistent allergic rhinitis. *Allergy* 2004; 59:320-6.
 14. Bousquet J, Khaltayev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. World Health Organization; GA(2)LEN; AllerGen: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen**). *Allergy* 2008; 63 (Suppl. 86): 8-160
 15. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. *J Allergy Clin Immunol* 1995; 96(6 Pt 1):971-9.
 16. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005: *Am J Respir Crit Care Med* 2005; 171(8):912-30.
 17. Gratziau C, Lignos M, Dassiou M, Roussos C. Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. *Eur Respir J* 1999; 14(4):897-901.
 18. Gratziau C, Rovina N, Makris M, Simoes DM, Papapetropoulos A, Roussos C. Breath markers of oxidative stress and airway inflammation in seasonal allergic rhinitis. *Int J Immunopathol Pharmacol* 2008; 21(4):949-57.
 19. Cardinale F, de Benedictis FM, Muggeo V, Giordano P, Loffredo MS, Iacoviello G, et al. Exhaled nitric oxide, total serum IgE and allergic sensitization in childhood asthma and allergic rhinitis. *Pediatr Allergy Immunol* 2005; 16(3):236-42.
 20. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D, et al. Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. *Clin Exp Allergy* 2003; 33(11):1506-11.
 21. Downie SR, Andersson M, Rimmer J, Leuppi JD, Xuan W, Akerlund A, et al. Association between nasal and bronchial symptoms in subjects with persistent allergic rhinitis. *Allergy* 2004; 59(3):320-6.
 22. Horvath I, Barnes PJ. Exhaled monoxides in asymptomatic atopic subjects. *Clin Exp Allergy* 1999; 29(9):1276-80.
 23. Prasad A, Langford B, Stradling JR, Ho LP. Exhaled nitric oxide as a screening tool for asthma in school children. *Respir Med* 2006; 100(1):167-73.
 24. Olin AC, Alving K, Toren K. Exhaled nitric oxide relation to sensitization and respiratory symptoms. *Clin Exp Allergy* 2004; 34(2):221-6.
 25. Prieto L, Uixera S, Gutierrez V, Bruno L. Modifications of Airway Responsiveness to adenosine 5-monophosphate and exhaled nitric oxide Concentrations after the pollen season in subjects with pollen-induced rhinitis. *Chest* 2002; 122(3):940-7.
 26. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. *Thorax* 1998; 53(2):91-5.
 27. Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. *Ann Allergy Asthma Immunol* 2003; 91(4):398-404.
 28. Silvestri M, Spallarossa D, Battistini E, Fregonese B, Rossi GA. Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma. *Thorax* 2000; 55(6):484-8.
 29. van Rensen ELJ, Straathof K, Veselic-Charvat M, Zwinderman A, Bel E, Sterk P. Effects of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and

- exhaled nitric oxide levels in patients with asthma. *Thorax* 1999; 54(5):403-8.
30. Prieto L, Gutierrez V, Uixera S. Exhaled nitric oxide and bronchial responsiveness to adenosine 5-monophosphate Concentrations after the pollen season in subjects with allergic rhinitis. *Chest* 2002; 122(3):940-7.
 31. Porsbjerg C, Brannan JD, Anderson SD, Backer V. Relationship between airway responsiveness to mannitol and to metacholine and markers of airway inflammation, peak flow variability and quality of life in asthma patients. *Clin Exp Allergy* 2008; 38(1):43-50.
 32. Ciprandi G, Cirillo I, Vizzaccaro A, Monardo M, Tosca MA. Early bronchial airflow impairment in patients with persistent allergic rhinitis and bronchial hyperreactivity. *Respir Med* 2005; 99(12):1606-12.
 33. Marseglia GL, Cirillo I, Vizzaccaro A, Klersy C, Tosca MA, La Rosa M, et.al. Role of forced expiratory flow at 25-75% as an early marker of small airways impairment in subjects with allergic rhinitis. *Allergy Asthma Proc* 2007; 28(1):74-8.
 34. Mete N, Sin A, Gulbahar O, Erdinc M, Sebik F, Kokuludag A. The determinants of bronchial hyperresponsiveness in patients with allergic rhinitis. *Ann Allergy Asthma Immunol* 2004; 93(2):193-9.
 35. Kharitonov SA, Rajakulasingam K, O'Connor B, Durham SR, Barnes PJ. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. *J Allergy Clin Immunol* 1997; 99(1 Pt 1):58-64.
 36. Moody A, Fergusson W, Wells A, Bartley J, Kolbe J. Nasal levels of nitric oxide as an outcome variable in allergic upper respiratory tract disease: Influence of atopy and hayfever on nNO. *Am J Rhinol* 2006; 20(5):425-9.
 37. Ciprandi G, Cirillo I, Klersy C. Lower airways may also be affected in asymptomatic patients with recent onset of allergic rhinitis. *Laryngoscope* 2010; 120(7):1288-91.